Abstract
EE190 From Clinical Trials to RWE: Defining Faricimab Value Drivers in Neovascular Age Related Macular Degeneration Through a Cost Utility Analysis
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have